Olivier Taelman is an experienced MedTech leader, joining Nyxoah in July 2019 as Chief Operating and Commercial Officer and subsequently being appointed as CEO in November 2019. Olivier spent 7 years in commercial healthcare at Eli Lilly and Sanofi Aventis leading specific Business Units. He spent 15 years within the field of neuromodulation at Medtronic, managing EMEA at Stryker NeuroVascular and serving a neuromodulation company Nevro where he was responsible for building the European business during the successful NASDAQ IPO.
Loïc Moreau has served as our Chief Financial Officer since January 2022. He is a seasoned leader with more than 20 years of experience in Finance having held senior roles at GSK notably in M&A/Corporate Development or Country-CFO across different geographies. Prior to this, he started his career at EY (External Audit) and PwC (Corporate Finance). Loic holds a master from ESSCA Management School (France) and Master in Finance from Solvay University (Belgium).
Dr. Boon joined Nyxoah after a 24 year academic and clinical career focusing on treating obstructive sleep apnea (OSA). He is dual boarded in Otolaryngology - Head and Neck Surgery and is one of the pioneers in the use of hypoglossal nerve stimulation therapy (HGNS). He is internationally recognized as one of the most experienced surgeons in performing HGNS procedures. He has lectured worldwide on OSA, has numerous publications and is co-editor of the first book on HGNS.
Bruno Onkelinx has 25 years of experience in highly regulated industries with the last 15 years in active implantable medical devices at Cochlear. At Cochlear he built successful teams while managing international research & development and manufacturing operations across Europe-Belgium and the US-Colorado. He led several core Cochlear products from ideation through development to commercial approval and manufacturing. During his last years at Cochlear, Bruno was leading global incubation activities supporting business development activities and external medical device start/scale-ups.
An Moonen joined Nyxoah in December 2020 as General Counsel, bringing over 20 years of experience. After 11 years at Linklaters (Corporate M&A), she joined cell therapy company TiGenix in 2011 where she oversaw all legal and compliance matters as General Counsel and Company Secretary. An was involved in various strategic licensing, financing and M&A transactions, including TiGenix’ Nasdaq IPO and its takeover by Takeda. An holds a law degree from the KU Leuven and a Master of Laws (LLM) degree from New York University School of Law. She is a member of the New York Bar.
Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by strong operational execution. Scott is a passionate advocate for people and talent development. Scott graduated with the Superintendent’s Award for Excellence (Star Wreath) from the United States Military Academy at West Point, NY. After serving as a Captain in the U.S. Army, Scott received his MBA from the University of Minnesota, Carlson School of Management.
Jeyakumar Subbaroyan has 14 years of experience in clinical and pre-clinical neuromodulation research in the fields of urology, migraine, spinal cord injury, and various chronic pain conditions. He has successfully executed multiple clinical studies across the US, Europe and Australia managing diverse global teams. He has 4 issued patents and over 20 peer-reviewed publications. Prior to Nyxoah, Jey held various positions of increasing responsibility in medical device companies including Johnson & Johnson, Spinal Modulation Inc. (acquired by St. Jude Medical), Nevro Corp. and Onward Medical Inc. to name a few.
Francis is a seasoned global regulatory and quality executive in the healthcare industry, with more than 25 years of extensive experience in the highly regulated medical device sector. He has made significant contributions to prominent organizations leading Regulatory and/or Quality functions at Medtronic, Waters, and Philips . In his responsibility as a leader in Quality and Regulatory, Francis introduced several innovative products to the market. He is known for his agility and his ability to drive innovative solutions and transformation across a wide range of therapies, markets, and products. Francis holds an MBA, and a dual bachelor’s degree in Chemistry & Biological Sciences.
Rémi Renard has more than 20 years of experience in Sales and Marketing. Throughout his career he has held multiple sales and marketing positions in medical device firms, mostly in the Cardiac Rhythm Management and OSA fields at Resmed, Boston Scientific and St. Jude Medical. Notably he successfully led sales and marketing activities related to the introduction in international markets of the first to market leadless pacemaker.
Doug brings over 20 years of experience in the medical device industry, with a proven track record in sales leadership and market development. Prior to joining Nyxoah, Doug held senior roles at leading healthcare companies, driving growth and establishing high-performing sales teams.
Inge has more than 20 years of HR experience, joining Nyxoah from Sterigenics, where she was HR Director for the EMEAA region. At Sterigenics, her primary projects focused on organization structure, workforce planning, and compensation and benefits strategy. Prior to Sterigenics, she spent nearly 10 years at Edwards Lifesciences, where she started as an HR Manager and progressed to become a Country Manager for Benelux and HR Business Partner to the European organization.